Evidence map›Paper›PMID 31938309›Full record

ArticleInternational journal of clinical and experimental pathology2018

The role of fenhexamid on the proliferation of ovarian cancer BG-1 cells.

Anxing Fei, Handong Fu, Hong Jiang, Liping Wei, Hongxia Zhang, Anqiong Fei, Yan Zhang, Tiantian Zou, Shuzhen Gao, Lin Li and 4 more

RetractedOpen access · greenAbstract readRetracted Publication
PubMed Full text at PMC
In one paragraph

Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 79% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Anxing FeiLaboratory Department (Clinical Laboratory) of Huangshi Maternal and Child Health Hospital Huangshi 435000, Hubei, P. R. China.
Handong FuXiaogan Hospital Affiliated to Wuhan University of Science and Technology Xiaogan 432100, Hubei, P. R. China.
Hong JiangLaboratory Department (Clinical Laboratory) of Huangshi Maternal and Child Health Hospital Huangshi 435000, Hubei, P. R. China.
Liping WeiLaboratory Department (Clinical Laboratory) of Huangshi Maternal and Child Health Hospital Huangshi 435000, Hubei, P. R. China.
Hongxia ZhangLaboratory Department (Clinical Laboratory) of Huangshi Maternal and Child Health Hospital Huangshi 435000, Hubei, P. R. China.
Anqiong FeiDaye General Hospital Huangshi 435100, Hubei, P. R. China.
Yan ZhangLaboratory Department (Clinical Laboratory) of Huangshi Maternal and Child Health Hospital Huangshi 435000, Hubei, P. R. China.
Tiantian ZouLaboratory Department (Clinical Laboratory) of Huangshi Maternal and Child Health Hospital Huangshi 435000, Hubei, P. R. China.
Shuzhen GaoLaboratory Department (Clinical Laboratory) of Huangshi Maternal and Child Health Hospital Huangshi 435000, Hubei, P. R. China.
Lin LiDepartment of Obstetrics and Gynecology, Xiangyang Central Hospital, Hubei University of Arts and Science Xiangyang 441021, Hubei, P. R. China.
Hong JiangDepartment of Obstetrics and Gynecology, Xiangyang Central Hospital, Hubei University of Arts and Science Xiangyang 441021, Hubei, P. R. China.
Min ZhouDepartment of Obstetrics and Gynecology, Xiangyang Central Hospital, Hubei University of Arts and Science Xiangyang 441021, Hubei, P. R. China.
Hui XingDepartment of Obstetrics and Gynecology, Xiangyang Central Hospital, Hubei University of Arts and Science Xiangyang 441021, Hubei, P. R. China.
Yanli HuangDepartment of Obstetrics and Gynecology, Xiangyang Central Hospital, Hubei University of Arts and Science Xiangyang 441021, Hubei, P. R. China.
Huangshi Central Hospital · CNHubei University of Arts and Science · CNThe Central Hospital of Xiao gan · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To study the influence of fenhexamid in pesticide residue to the human ovarian cancer BG-1 cell proliferation. Detecting the effectiveness of 17β-estradiol, fenhexamid and Fulvestrant to BG-1 cell proliferation by MTT, and detecting the expression levels of cyclin D1 and cyclin E by Western blot. Fenhexamid can promote BG-1 cell proliferation for its estrogen-like effect. On the other hand, it can help to improve the expression levels of cyclin D1 and cyclin E in BG-1 cells which is regulated by ER-dependent pathway. And 17β-estradiol is also regulated by the same way. The existence of fenhexamid can promote ovarian cancer cell proliferation, so for patients with ovarian cancer, fenhexamid in pesticide residue may make medical conditions worse.

Indexed as

fenhexamidOvarian cancerpesticide residues

Identifiers

PMID31938309
PMCPMC6958182
OpenAlexW3026087374

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.